Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2005

View Archived Issues

CYT006-AngQb: preclinical validation and further study in healthy volunteers

Novel lactam sodium channel blocker displays anticonvulsant activity

sanofi -aventis profiles pipeline development

Pfizer's new nNOS inhibitors demonstrate efficacy for pain and stroke

Antidepressant effects of two new triple reuptake inhibitors

Preclinical efficacy of FG-3019 against diabetes-associated metabolic/cardiovascular complications

Good safety and pharmacokinetic data reported for ANA-975 in monkeys and humans

Clinical evidence supports the use of CpG-10101 in hepatitis C

Gilead and Roche settle Tamiflu dispute

Johnson & Johnson and Guidant amend acquisition agreement

ev3 and Micro Therapeutics announce merger agreement

Medarex anticipates milestone payment from Bristol-Myers Squibb

Phase II study evaluates TroVax with IL-2 for metastatic renal cell carcinoma

Pivotal Veronate phase III study completes enrollment

Abraxane licensed to Taiho for Japan

Xenome begins phase I/II study for XEN-2174 for severe intractable pain

SNS-595 studied for refractory acute leukemia in phase I trial

Cardioprotective effects of a new plasminogen activator inhibitor

Reverse D-4F: potential in atherosclerosis

Anticancer potential of novel chalcones

AC-260584: an atypical M1 agonist with an ectopic binding site

ABT-127: Abbott's new D3 receptor antagonist targeted as an antipsychotic

Enhanced antitumor activity with IMC-3G3 plus doxorubicin in a leiomyosarcoma model

GNS-037: A novel HCV entry inhibitor

Novel HERG channel activator NS-1643 under investigation for treatment of arrhythmias

Shanghai Sunway Biotech's H101 approved for refractory nasopharyngeal cancer

Recent CNRS patent discloses novel MRI agents

Recent patents disclose novel agents for the treatment of endocrine-related disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...